Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Scholar Rock is a biopharmaceutical company specializing in the discovery and development of monoclonal antibodies targeting latent growth factors, primarily within the TGF-β superfamily. Its proprietary platform enables selective inhibition of growth factor activation in disease microenvironments, aiming to treat neuromuscular disorders, cancer, fibrosis, and cardiometabolic diseases. The company’s lead candidate, apitegromab, targets muscle atrophy in SMA, while others focus on cancer and fibrosis, emphasizing precision medicine and innovative therapeutic approaches.
This description was generated via AI from an annual report. Updated about 1 year ago.